Cullinan Therapeutics, Inc. (CGEM) › Operating Cash FlowCullinan Therapeutics, Inc. (CGEM) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2020: -$29.77M2021: -$43.43M2022: -$126.66M2023: -$134.28M2024: -$145.30M2025: -$175.75M-$175.75M2020Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$175.75M-21.0%2024-$145.30M-8.2%2023-$134.28M-6.0%2022-$126.66M-191.6%2021-$43.43M-45.9%2020-$29.77M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share